C6 B. burgdorferi (Lyme) ELISA
Peptide ELISA eliminates vaccine cross-reactivity
CAMBRIDGE, Mass.....May 31, 2001….. This new Lyme ELISA was recently cleared for in vitro diagnostic use by the FDA. The kit is the first to detect human antibodies to B. burgdorferi using the C6 peptide antigen, recently shown to be a highly accurate marker for Lyme disease. In a comparative study, the C6 ELISA yielded a 10-fold reduction in the number of false positive results, while demonstrating sensitivity of 100% in early Lyme disease (up to 1 month after onset) and 98% in late stage disease (1 year or more after onset). Overall, concordance of C6 ELISA with Western Blot results was 97%. Unlike many other Lyme screening tests, this test does not yield false positive results on individuals vaccinated with the Lymerix® vaccine*. These advantages will enable clinicians to diagnose or rule out the disease more quickly, with less re-testing. As an added benefit, the C6 test detects infection with European Lyme strains B. garinii and B. afzelii. The kit includes a 96-well breakaway microplate, ready to use reagents and controls.
* Recombinant OspA vaccine against Lyme disease, manufactured by GlaxoSmithKline Biologicals
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras ac orci. Quisque vitae felis et tellus consectetur cursus. Integer eu enim ut nisl semper tincidunt. Fusce aliquam vestibulum enim. Sed bibendum, ipsum id tincidunt convallis, urna eros placerat lectus, vel accumsan turpis dolor in libero. Mauris vitae leo. Praesent euismod. Praesent non lorem. Duis euismod malesuada nibh. Nullam mattis, erat nec tristique molestie, nisl dolor commodo mi, lacinia placerat elit nulla a nisl. Suspendisse facilisis, sapien eget feugiat imperdiet, nisi justo gravida augue, id pulvinar orci tortor lacinia enim. Integer vitae dui. Aenean arcu dolor, volutpat et, cursus et, pharetra a, nisl. Pellentesque scelerisque, justo at suscipit eleifend, metus nulla pharetra lectus, vitae consequat lorem eros vitae velit. Nullam leo. Etiam tempor pede vitae quam. Ut enim mi, tristique vel, molestie at, sagittis in, elit.
Duis commodo lorem sed enim. Donec ut risus blandit pede laoreet sagittis. Vestibulum sodales vestibulum urna. Maecenas quis lacus. In consectetur tortor eu tortor. Sed eget augue. Sed vitae metus in pede sodales varius. Mauris in nulla ut lorem auctor porttitor. Proin odio. Quisque vestibulum dui at erat. Quisque ac dui. Praesent pharetra. Suspendisse potenti. Fusce commodo. Aenean faucibus justo ac ligula. In hac habitasse platea dictumst.
Suspendisse potenti. Pellentesque eu orci. Duis scelerisque. Donec elementum ipsum a pede. Pellentesque tellus. Nunc purus pede, tincidunt ac, imperdiet at, varius sit amet, est. Nulla aliquam vulputate ante. Sed vehicula ullamcorper ligula. Quisque nec enim in ligula blandit ullamcorper. Maecenas cursus. Nunc ultricies. Maecenas id dolor. Nulla facilisi. Quisque suscipit turpis ac dolor. Etiam ligula.
Praesent purus. Nullam rhoncus lobortis augue. Integer quam urna, fringilla mattis, hendrerit id, consequat at, massa. Proin enim. Sed mattis mollis leo. Mauris at urna. Nulla vel lacus quis justo semper rhoncus. Aliquam gravida pede vitae mauris. Duis feugiat pellentesque risus. Aliquam erat volutpat.
Return to News & Events
